Cargando…

Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer

SIMPLE SUMMARY: In this exploratory analysis of a randomized controlled trial, we found that dynamic changes in simple laboratory-based markers such as prostate-specific antigen (PSA) could be used to predict survival in patients with metastatic prostate cancer that is sensitive to hormonal manipula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Soumyajit, Sun, Yilun, Wallis, Christopher J. D., Kishan, Amar U., Morgan, Scott C., Spratt, Daniel E., Malone, Shawn, Saad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486494/ https://www.ncbi.nlm.nih.gov/pubmed/37686668 http://dx.doi.org/10.3390/cancers15174392

Ejemplares similares

A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer
por: Burgess, Laura, et al.
Publicado: (2021)

Implications of local failure on overall prognosis in aggressive prostate cancer
por: Mula-Hussain, Layth, et al.
Publicado: (2020)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer
por: Ma, Ting Martin, et al.
Publicado: (2023)

TRPM8 protein expression in hormone naïve local and lymph node metastatic prostate cancer
por: Lunardi, Andrea, et al.
Publicado: (2021)

Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options
por: Zaorsky, Nicholas G., et al.
Publicado: (2020)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

A lower psoas muscle index predicts a poorer prognosis in metastatic hormone‐naïve prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study
por: Malone, Shawn, et al.
Publicado: (2022)

Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer
por: Wallis, Christopher J D, et al.
Publicado: (2021)

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
por: Reichert, Zachery R., et al.
Publicado: (2021)

Hormone naïve prostate cancer: predicting and maximizing response intervals
por: Moul, Judd W
Publicado: (2015)

Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer
por: Cook, Kiri, et al.
Publicado: (2020)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China
por: Zhang, Yang, et al.
Publicado: (2023)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Local failure in high grade prostate cancer: the importance of local and systemic therapy
por: Kishan, Amar U., et al.
Publicado: (2020)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis
por: Di Francesco, Simona, et al.
Publicado: (2013)

Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer
por: Valta, Maija, et al.
Publicado: (2020)

Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN): a randomized phase II study protocol
por: McClelland, Shearwood, et al.
Publicado: (2023)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

Acute toxicities after extremely hypofractionated radiotherapy for prostate cancer: lessons from HYPO-RT-PC and PACE-B
por: Juarez, Jesus E., et al.
Publicado: (2020)

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
por: Narita, Takuma, et al.
Publicado: (2021)

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
por: Merson, S, et al.
Publicado: (2014)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Image-guided radiotherapy for prostate cancer
por: Dang, Audrey, et al.
Publicado: (2018)

Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate
por: Amato, Robert J., et al.
Publicado: (2008)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases
por: Schmidt, Linnéa, et al.
Publicado: (2018)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
por: Nakanishi, Shotaro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k3om3r64qq9j9e78t3p6kvcha7